Australia is experience innovative treatment for excess weight: Retatrutide. This new dual agonist – working on both GLP-1 and GIP receptors – has promising outcomes in clinical research, suggesting considerable decreases in BMI. While availability hasn't occurred with the Therapeutic Goods Administration (TGA), several Australians dealing with